Filter by tags: Canada Neoplasm Clear all tag filters
5 news articles found
Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.
Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.
According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.
- Source: Nucnet
- Date: Friday, 14 April 2023
- Original article: nucnet.org/news/sector-aims-to-tackle-isotope-supply-problems-as-excitement-grows-over-targeted-therapies-4-4-2023
The production of cobalt-60 is critical to healthcare and, with demand soaring, the challenge is to expand supply, writes Martin Comben from the International Irradiation Association.
- Source: World Nuclear News
- Date: Wednesday, 29 March 2023
- Original article: world-nuclear-news.org/Articles/The-critical-production-of-cobalt-60-in-nuclear-re
The commercial production of lutetium-177 (Lu-177) has begun using a new isotope production system (IPS) that was installed in unit 7 of the Bruce plant in Ontario, Canada, during a planned maintenance outage earlier this year.
- Source: World Nuclear News
- Date: Thursday, 27 October 2022
- Original article: world-nuclear-news.org/Articles/Bruce-7-starts-producing-innovative-therapeutic-is
Lutetium-177 (Lu-177) has been produced using a new isotope production system (IPS) that was installed in unit 7 of the Bruce plant in Ontario, Canada, during a recent planned maintenance outage. It marks the first time the short-lived medical isotope has been produced in a commercial nuclear power reactor.
- Source: World Nuclear News
- Date: Thursday, 23 June 2022
- Original article: world-nuclear-news.org/Articles/Canadian-Candu-produces-cancer-therapy-isotope
TRIUMF, Canada’s particle accelerator centre, and Canadian Nuclear Laboratories (CNL) announced on 27 September that they have agreed to pursue a strategic partnership around the commercial production of the medical isotope, Actinium-225, as the basis of new cancer treatments. Actinium-225 is an alpha-emitting isotope with a short half-life that can be combined with a protein or antibody that specifically targets cancer cells.
- Source: NEI Magazine
- Date: Tuesday, 02 October 2018
- Original article: neimagazine.com/news/newscanadian-laboratories-collaborate-to-produce-actinium-225-6779321